搜索优化
Rewards
English
搜索
Copilot
图片
视频
地图
资讯
购物
更多
航班
旅游
酒店
房地产
笔记本
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
时间不限
过去 1 小时
过去 24 小时
过去 7 天
过去 30 天
按时间排序
按相关度排序
HealthDay on MSN
1 天
Endovascular Therapy Improves Left Ventricular Diastolic Function in HFpEF
For patients with heart failure with preserved ejection fraction (HFpEF), endovascular treatment (EVT) improves left ...
1 天
Endovascular therapy improves left ventricular diastolic function in heart failure with ...
For patients with heart failure with preserved ejection fraction (HFpEF), endovascular treatment (EVT) improves left ...
MassDevice
1 天
AngioDynamics kicks off study of thrombectomy system for pulmonary embolism
AngioDynamics announced today that it launched a new trial evaluating its AlphaVac F18 system in treating pulmonary embolism ...
News Medical
1 天
Advanced Cardiotoxicity Testing Using Multi-Channel iPSC Cardiomyocytes
Multi-channel models enhance cardiotoxicity testing, offering more accurate and human-relevant insights for safer drug ...
thecardiologyadvisor.com
1 天
Rethinking Beta-Blocker Use Following Acute Myocardial Infarction
Christopher Granger, MD, Gregg Fonarow, MD, and Carlin S Long, MD, discuss the use of beta-blocker therapy following acute MI ...
2 天
Evaluating Cytokinetics’ Market Position Amidst Emerging Competitive Threats
Bank of America Securities analyst Jason Zemansky has maintained their neutral stance on CYTK stock, giving a Hold rating on September 9.
Business Wire
2 天
AngioDynamics Initiates RECOVER-AV Clinical Trial Assessing AlphaVac F18⁸⁵ System in ...
AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vasc ...
2 天
Edgewise: Stock Is Bouncing On Heart Disease Drug Data, Albeit From Just 7 Patients (Rating ...
Edgewise's lead drug, Sevasemten, remains unchanged in its potential, with ongoing pivotal studies for Becker Muscular ...
2 天
Buy Rating Affirmed on Edgewise Therapeutics’ EDG-7500 for HCM Treatment Due to Promising ...
Leerink Partners analyst Joseph Schwartz reiterated a Buy rating on Edgewise Therapeutics (EWTX – Research Report) today and set a price ...
2 天
on MSN
Why Edgewise Therapeutics Stock Is Up 50% on Thursday
Shares of biopharma outfit Edgewise Therapeutics (NASDAQ: EWTX) soared more than 50% today, reaching a three-year high ...
Endovascular Today
2 天
AngioDynamics Begins RECOVER-AV Trial in Europe for AlphaVac F18
AngioDynamics, Inc. announced the launch of the RECOVER AV trial of the company’s AlphaVac F18⁸⁵ multipurpose mecha ...
2 天
Edgewise Therapeutics Stock Shoots Higher On Promising Early Results For Thickened Heart ...
Edgewise Therapeutics announced topline data from Phase 1 and Phase 2 trials of EDG-7500 for obstructive hypertrophic ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果
反馈